NVCT News and Press, Nuvectis Pharma Inc.

2026-02-23 17:38:54 ET Nuvectis Pharma, Inc. (NVCT) - This analysis reviews how the stock price reacted during the last 12 earnings periods. The average open to high on the day of earnings was 3.53%. The average open to low on the day of earnings was -6.07%. The average open to ...

2026-02-23 17:33:55 ET Nuvectis Pharma, Inc. (NVCT) - Following Earnings Price Analysis was done using last 12 quarters historical earnings. Opening Gap Moves The historical opening gap move in NVCT stock price following earnings has averaged ±1.53% , with a median of 1.63%. ...

2026-02-11 08:51:36 ET More on Nuvectis Pharma Seeking Alpha’s Quant Rating on Nuvectis Pharma Historical earnings data for Nuvectis Pharma Financial information for Nuvectis Pharma Read the full article on Seeking Alpha For further details see...

FORT LEE, N.J., Feb. 11, 2026 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, ...

2026-01-05 16:15:00 ET Today's pharmaceutical stocks are facing the challenges of government-imposed drug price caps, waning demand for COVID-19 vaccines and global stock market upheaval. However, the industry's major underlying drivers — higher rates of cancer and chronic di...

Fort Lee, NJ, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, today announced the initiation...

Fort Lee, NJ, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT, the “Company”), a clinical stage biopharmaceutical company focused on the development of innovative precision medicines for the treatment of serious conditions of unmet medical need in oncology, tod...

2025-11-04 12:31:33 ET More on Nuvectis Pharma Seeking Alpha’s Quant Rating on Nuvectis Pharma Historical earnings data for Nuvectis Pharma Financial information for Nuvectis Pharma Read the full article on Seeking Alpha For further details see...

FORT LEE, N.J., Nov. 04, 2025 (GLOBE NEWSWIRE) -- In a release issued under the same headline on November 4, 2025 at 07:30 ET by Nuvectis Pharma, Inc. (NASDAQ: NVCT), the tables were not included. The tables have been added and the corrected release follows: NXP900 Phase 1b program initiate...

NXP900 Phase 1b program initiated; single agent study underway, aiming to provide preliminary evidence of clinical efficacy in patients with molecularly and histologically defined advanced cancers; initiation of the combination portion of the program expected by year-end NXP900 Phase 1a d...